Top

Orphanet Journal of Rare Diseases

Published in:

Open Access 01-12-2024 | Research

Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II

Authors: Karen S. Yee, Sandy Lewis, Emily Evans, Carla Romano, David Alexanderian

Published in: Orphanet Journal of Rare Diseases | Issue 1/2024

Abstract

Background

Approximately two-thirds of patients with mucopolysaccharidosis II (MPS II) have a severe, neuronopathic phenotype, characterized by somatic, cognitive, and behavioral issues. Current standard of care for the treatment of MPS II is enzyme replacement therapy with intravenous recombinant human iduronate-2-sulfatase (idursulfase). To target cognitive manifestations of MPS II, idursulfase has been formulated for intrathecal administration into the cerebrospinal fluid (idursulfase-IT). In accordance with recommendations for patient-focused drug development, semi-structured interviews were conducted to assess caregiver experiences and observations in a 52-week phase 2/3 trial of idursulfase-IT, in addition to intravenous idursulfase in pediatric patients with neuronopathic MPS II, or a substudy which enrolled patients younger than 3 years old, all of whom received idursulfase-IT.

Results

Overall, 46 caregivers providing care for 50 children (mean [range] age 7.9 [3–17] years at interview) took part in a single 60-min exit interview; six of these children had participated in the substudy. Qualitative and quantitative data were obtained demonstrating the burden of MPS II experienced by caregivers and their families. Following participation in the trials, 39 (78%) of the children were reported by their caregivers to have experienced improvements in the symptoms and impact of disease. Of those with improvements, 37 (95%) experienced cognitive improvements and 26 (67%) experienced emotional/behavioral improvements. Overall, 43 children (86%) were rated by caregivers as having moderate or severe symptoms before the trials; after the trials, 28 children (56%) were considered to have mild or no symptoms. For the six children who participated in the substudy, these proportions were 83% and 100%, respectively. Caregivers’ qualitative descriptions of trial experiences suggested improvements in children’s verbal and non-verbal functioning and spatial and motor skills, as well as a positive impact on family life.

Conclusions

This study revealed caregiver-reported improvements in children’s MPS II symptoms and the impact of the disease on patients and their families. There was a trend for cognitive improvement and a reduction in severity of MPS II symptoms. After many years of extensive review and regulatory discussions of idursulfase-IT, the clinical trial data were found to be insufficient to meet the evidentiary standard to support regulatory filings.

Available only for authorised users

van der Lee JH, Morton J, Adams HR, Clarke L, Eisengart JB, Escolar ML, et al. Therapy development for the mucopolysaccharidoses: updated consensus recommendations for neuropsychological endpoints. Mol Genet Metab. 2020;131(1–2):181–96.PubMed

Verheyen S, Blatterer J, Speicher MR, Bhavani GS, Boons GJ, Ilse MB, et al. Novel subtype of mucopolysaccharidosis caused by arylsulfatase K (ARSK) deficiency. J Med Genet. 2022;59(10):957–64.CrossRefPubMed

Federhen A, Pasqualim G, de Freitas TF, Gonzalez EA, Trapp F, Matte U, et al. Estimated birth prevalence of mucopolysaccharidoses in Brazil. Am J Med Genet A. 2020;182(3):469–83.CrossRefPubMed

Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, et al. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121(3):227–40.CrossRefPubMedPubMedCentral

D’Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment. Int J Mol Sci. 2020;21(4):1258–96.CrossRefPubMedPubMedCentral

Burton BK, Giugliani R. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls. Eur J Pediatr. 2012;171(4):631–9.CrossRefPubMedPubMedCentral

Young ID, Harper PS. The natural history of the severe form of Hunter’s syndrome: a study based on 52 cases. Dev Med Child Neurol. 1983;25(4):481–9.CrossRefPubMed

Eisengart JB, King KE, Shapiro EG, Whitley CB, Muenzer J. The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome. Mol Genet Metab Rep. 2020;22:100549.CrossRefPubMed

Holt JB, Poe MD, Escolar ML. Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics. 2011;127(5):e1258–65.CrossRefPubMed

10.

Jones SA, Almassy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II - a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009;32(4):534–43.CrossRefPubMed

11.

Needham M, Packman W, Quinn N, Rappoport M, Aoki C, Bostrom A, et al. Health-related quality of life in patients with MPS II. J Genet Couns. 2015;24(4):635–44.CrossRefPubMed

12.

Stapleton M, Kubaski F, Mason RW, Yabe H, Suzuki Y, Orii KE, et al. Presentation and treatments for mucopolysaccharidosis type II (MPS II; Hunter syndrome). Expert Opin Orphan Drugs. 2017;5(4):295–307.CrossRefPubMedPubMedCentral

13.

Harrington M, Hareendran A, Skalicky A, Wilson H, Clark M, Mikl J. Assessing the impact on caregivers caring for patients with rare pediatric lysosomal storage diseases: development of the Caregiver Impact Questionnaire. J Patient Rep Outcomes. 2019;3(1):44.CrossRefPubMedPubMedCentral

14.

Conner T, Cook F, Fernandez V, Rangel-Miller V. An online survey of burden of illness in families with mucopolysaccharidosis type II children in the United States. Mol Genet Metab Rep. 2019;21:100499.CrossRefPubMedPubMedCentral

15.

McBride KL, Berry SA, Braverman N, ACMG Therapeutics Committee. Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22(11):1735–42.CrossRefPubMed

16.

BioSpace.com. CANbridge pharmaceuticals receives Chinese marketing approval for Hunterase® first enzyme replacement therapy for Hunter syndrome in China, https://www.biospace.com/article/releases/canbridge-pharmaceuticals-receives-chinese-marketing-approval-for-hunterase-first-enzyme-replacement-therapy-for-hunter-syndrome-in-china, 2020. Accessed 12 Oct 2023.

17.

JCR Pharmaceuticals Co., Ltd. Launch of IZCARGO® I.V. Infusion 10mg (JR-141: pabinafusp alfa) for treatment of MPS II (Hunter syndrome) in Japan, https://ssl4.eir-parts.net/doc/4552/tdnet/1974327/00.pdf, 2021. Accessed 12 Oct 2023.

18.

Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13(2):95–101.CrossRefPubMed

19.

Muenzer J, Giugliani R, Scarpa M, Tylki-Szymanska A, Jego V, Beck M. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the Hunter Outcome Survey (HOS). Orphanet J Rare Dis. 2017;12(1):161.CrossRefPubMedPubMedCentral

20.

Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465–73.CrossRefPubMed

21.

Burton BK, Jego V, Mikl J, Jones SA. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2017;40(6):867–74.CrossRefPubMed

22.

Calias P, Papisov M, Pan J, Savioli N, Belov V, Huang Y, et al. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS ONE. 2012;7(1):e30341.ADSCrossRefPubMedPubMedCentral

23.

Muenzer J, Bodamer O, Burton B, Clarke L, Frenking GS, Giugliani R, et al. The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr. 2012;171(1):181–8.CrossRefPubMed

24.

ClinicalTrials.gov. A study of tividenofusp alfa (DNL310) in pediatric participants with Hunter syndrome, https://classic.clinicaltrials.gov/ct2/show/NCT04251026, 2020. Accessed 12 Oct 2023.

25.

Harmatz P, Escolar M, Ficicioglu C, Giugliani R, Cho Y, Phillips D, et al. RGX-121 gene therapy for severe mucopolysaccharidosis type II (MPS II): interim neurodevelopmental outcomes and biomarker results (4164). Neurology. 2021;96(15 Supplement):4164.CrossRef

26.

Muenzer J, Burton BK, Harmatz P, Gutiérrez-Solana LG, Ruiz-Garcia M, Jones SA, et al. Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: results from a phase 2/3 randomized study. Mol Genet Metab. 2022;137(1–2):127–39.CrossRefPubMedPubMedCentral

27.

Muenzer J, Burton BK, Harmatz P, Gutiérrez-Solana LG, Ruiz-Garcia M, Jones SA, et al. Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II. Mol Genet Metab. 2022;137(1–2):92–103.CrossRefPubMedPubMedCentral

28.

Saulnier CA. Differential Ability Scales (DAS and DAS-II). In: Volkmar FR, editor. Encyclopedia of autism spectrum disorders. New York: Springer; 2013.

29.

Sparrow SS, Cicchetti DV, Balla DA. Vineland Adaptive Behavior Scales Vineland-II: survey forms manual. Minneapolis: Pearson; 2005.

30.

Barone R, Pellico A, Pittala A, Gasperini S. Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses. Ital J Pediatr. 2018;44(Suppl 2):121.CrossRefPubMedPubMedCentral

31.

US Food & Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. Center for Drug Evaluation and Research, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-collecting-comprehensive-and-representative-input, 2018. Accessed 12 Oct 2023.

32.

US Food & Drug Administration. Patient-focused drug development: methods to identify what is important to patients. Center for Drug Evaluation and Research, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-methods-identify-what-important-patients, 2022. Accessed 12 Oct 2023.

33.

US Food & Drug Administration. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. Center for Drug Evaluation and Research, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome, 2022. Accessed 12 Oct 2023.

34.

US Food & Drug Administration. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. Center for Drug Evaluation Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory, 2023. Accessed 12 Oct 2023.

35.

Muenzer J, Burton BK, Harmatz P, Amartino H, Jones SA, González Gutiérrez-Solana L, et al. Neurodevelopmental status and adaptive behavior of pediatric patients with Hunter syndrome: a longitudinal observational study. Mol Genet Metab. 2019;126(2):S103.

36.

Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res. 2020;9(1):1–9.CrossRefPubMedPubMedCentral

37.

Hoffmann F, Hoffmann S, Kunzmann K, Ries M. Challenging behavior in mucopolysaccharidoses types I-III and day-to-day coping strategies: a cross sectional explorative study. Orphanet J Rare Dis. 2020;15(1):275.CrossRefPubMedPubMedCentral

38.

da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database Syst Rev. 2016;2:8185.

39.

Taylor-Richardson KD, Heflinger CA, Brown TN. Experience of strain among types of caregivers responsible for children with serious emotional and behavioral disorders. J Emot Behav Disord. 2006;14:157–68.CrossRef

40.

Guffon N, Heron B, Chabrol B, Feillet F, Montauban V, Valayannopoulos V. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study. Orphanet J Rare Dis. 2015;10:43.CrossRefPubMedPubMedCentral

41.

Mengel E, Gaedeke J, Gothe H, Krupka S, Lachmann A, Reinke J, et al. The patient journey of patients with Fabry disease, Gaucher disease and mucopolysaccharidosis type II: a German-wide telephone survey. PLoS ONE. 2020;15(12):e0244279.CrossRefPubMedPubMedCentral

Title: Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II
Authors: Karen S. Yee
Sandy Lewis
Emily Evans
Carla Romano
David Alexanderian
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2024
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-024-03034-y

2024 ASCO Annual Meeting

Springer Medicine

Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II

Abstract

Background

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Trends in orphan medicinal products approvals in the European Union between 2010–2022

Impact of lipodystrophy on health-related quality of life: the QuaLip study

Correction: Estimating mortality in rare diseases using a population-based registry, 2002 through 2019

Biallelic variants in LARS1 induce steatosis in developing zebrafish liver via enhanced autophagy

NR1H4 disease: rapidly progressing neonatal intrahepatic cholestasis and early death

Causative role of a novel intronic indel variant in FBN1 and maternal germinal mosaicism in Marfan syndrome